GlaxoSmithKline has sold two travel vaccines to a Danish biotechnology company for almost €1 billion (US$1.11 billion) as it refocuses on its most profitable and innovative products, reported The Financial Times.
The UK drugmaker announced the decision to relinquish the brands, acquired from rival Novartis in 2015 as part of an asset swap that secured the Swiss company’s vaccines business, “supports GSK’s strategic intent to increase focus and reinvest in growth assets, innovation and a simplified supply chain in its vaccines business.”
GSK announced in December that it would split into a standalone pharmaceuticals and vaccines business and a separate consumer health joint venture with Pfizer, giving up on its current diversified corporate model.
On Monday, October 21, it announced the divestment of travel vaccines Rabipur, sold as Rabavert in the US, for the prevention of rabies, and Encepur for the prevention of tick-borne encephalitis, to Bavarian Nordic. The Danish company specialises in the research, development, and manufacture of cancer immunotherapies and vaccines for infectious diseases.
Full Content: Financial Times
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile’s Acquisition of Ka’ena Corporation Receives FCC Approval
Apr 26, 2024 by
CPI
UK Regulator Announces Two New Senior Executive Appointments
Apr 26, 2024 by
CPI
Paramount Global and Skydance Media Near Merger Deal, Eyeing CEO Change
Apr 26, 2024 by
CPI
BHP Unveils £31bn Mining Megamerger Proposal with Anglo American
Apr 25, 2024 by
nhoch@pymnts.com
ByteDance Prefers Shutdown Over Sale of TikTok Amid US Ban Threats
Apr 25, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI